Certified by Founder
Lodge
Tome Biosciences
start up
United States
- Watertown, Massachusetts
- 14/12/2023
- Series B
- $213,000,000
Tome Biosciences is the programmable genomic integration (PGI) company. Our technologies allow us to insert any genetic sequence of any size at any location in the genome with site-specific precision. We are writing the final chapter in genomic medicines, delivering cures to patients through cell and integrative gene therapies.
- Industry Biotechnology Research
- Website https://tome.bio/
- LinkedIn https://www.linkedin.com/company/tome-biosciences/about/
Avtal | $24,000,000 | (Mar 20, 2026)
games2gether | $5,202,945 | (Mar 20, 2026)
Claros | $30,000,000 | (Mar 20, 2026)
Latent | $80,000,000 | (Mar 20, 2026)
Corridor | $25,000,000 | (Mar 20, 2026)
RunSybil | $40,000,000 | (Mar 20, 2026)
Ezra AI Labs | $3,200,000 | (Mar 20, 2026)
Parallel(FRANCE) | $20,000,000 | (Mar 20, 2026)
Health Universe | $6,000,000 | (Mar 20, 2026)
PADO AI | $6,000,000 | (Mar 20, 2026)
Edra | $30,000,000 | (Mar 20, 2026)
Chalkie AI | $4,000,000 | (Mar 20, 2026)
Deeptune | $43,000,000 | (Mar 20, 2026)